Atopic dermatitis is the most common type of eczema, patients who are suffering with this disease have super sensitive skin and a decreased threshold for irritation. Additionally it misguides the immune system which leads to chronic diseases. The prevalence of atopic dermatitis are very common worldwide, that occur more often in infants and children. Atopic dermatitis includes hay fever, food allergies, atopic dermatitis, allergic asthma, and anaphylaxis.
Atopic dermatitis have various patterns depending on the age of patients. It can occur in the knees, inside the elbows, sides of the neck, wrists, ankles, and hands and has the tendency to develop papules which leads to rashes. It is characterized by low quantity of filaggrin protein that allows skin to become dry and reduces its protective abilities. Additionally, the skin is very susceptible to infections, such as staphylococcal and streptococcal bacterial skin infections, warts, herpes simplex, and molluscum contagiosum. The atopic dermatitis market growth is majorly attributed to the increasing prevalence of atopic disorders, decreased quantity of protein called filaggrin in skin. Moreover, rising funding along with government support for research and development fuel the market of atopic dermatitis. Moreover, advancing technology in medical devices is adding fuel to the growth of the market.
Get a sample report at https://www.marketresearchfuture.com/sample_request/1610 .
According to a report published by the National Center for Biotechnology Information, in 2015, atopic dermatitis was recorded to affect around 20% of infants & children and 3% of adults globally
A research study published in the National Eczema Association, in 2016, shows that around 9.6 million children under the age of 18years, which is 13% of U.S. population, have atopic dermatitis. Additionally, in 2016, the United States spend around $314 million on health system to treat atopic dermatitis patients.
However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.
The global atopic dermatitis market is expected to grow at a CAGR of 8.2% during the forecast period 2017-2023.
The global atopic dermatitis market is segmented on the basis of types, by application, and by end user.
On the basis of the type, it is segmented into hormone, Erythropoietin, Monoclonal antibodies, Interferon, Calcitonin, and others.
On the basis of the application, it is segmented into Cancer, blood disorders, chronic diseases, infectious diseases, and others.
On the basis of end user, it is segmented into hospitals, clinics, and research centers.
The Americas dominate the global atopic dermatitis market owing to well-developed technology, increasing patient with low quantity of protein filaggrin, increasing prevalence atopic disorder, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region. Rising in the adoption of skin irritants such as soaps, detergents, perfumes, cosmetics and even water may inflame the skin.
Europe holds the second position in the global atopic dermatitis market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.
Asia Pacific is the fastest growing atopic dermatitis market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead to the use of advanced equipment, which, in turn, will increase the market growth of the atopic dermatitis in the region.
On the other hand, in the Middle East and Africa, blood disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.
Browse complete report at https://www.marketresearchfuture.com/reports/atopic-dermatitis-market .
Some of key the players in the market are Astellas Pharma Inc. (Japan), Sanofi S.A. (France), Regeneron Pharmaceuticals, Inc. (U.S.), Valeant Pharmaceuticals International, Inc (Canada), Anacor Pharmaceuticals Inc. (U.S.), Novartis International AG (Switzerland), Bristol-Myers Squibb (U.S.), Meda Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Galderma S.A. (Switzerland), Allergan Plc. (Republic of Ireland)
LIST OF TABLES
Table 1 Atopic Dermatitis Industry Synopsis, 2017-2023
Table 2 Global Atopic Dermatitis Market Estimates And Forecast, 2017-2023, (USD Million)
Table 3 Global Atopic Dermatitis Market By Region, 2017-2023, (USD Million)
Table 4 Global Atopic Dermatitis Market By Types, 2017-2023, (USD Million)
Table 5 Global Atopic Dermatitis Market By Application, 2017-2023, (USD Million)
Table 6 Global Atopic Dermatitis Market By End Users, 2017-2023, (USD Million)
Market Research Future
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312